Trials / Completed
CompletedNCT02239172
PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine
A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purposes of this study is to evaluate and compare the safety, reactogenicity, and tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PA83-FhCMB |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-09-12
- Last updated
- 2016-05-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02239172. Inclusion in this directory is not an endorsement.